Tirzepatide Dosage Chart: Week-by-Week Titration Schedule

Your tirzepatide dose on week 1 is 2.5 mg. By week 21, it can reach 15 mg — but the path between those numbers is where most people either succeed or struggle.

The titration schedule exists for a reason: jumping too fast wrecks your GI system and often leads people to quit. Moving too slow can stall weight loss when your body is ready for more. This chart gives you the full picture — week by week, dose by dose — for both brand-name pens (Mounjaro and Zepbound) and compounded tirzepatide vials.

2.5 mg

Mandatory starting dose
for all patients

~21%

Average body weight lost
at max dose over 72 weeks

4 weeks

Minimum time at each
dose before advancing

Key Takeaways:

Tirzepatide starts at 2.5 mg weekly and escalates in 2.5 mg steps every 4+ weeks
The full titration from start to max dose (15 mg) takes a minimum of 20 weeks
Mounjaro (diabetes) and Zepbound (weight loss) use identical dosing schedules — same molecule, different labels
Compounded tirzepatide follows the same mg amounts but comes in vials with different concentrations (5, 10, or 20 mg/mL)
You don't have to reach 15 mg — many patients maintain results at 5–10 mg long-term
Side effects peak during dose increases and usually settle within 1–2 weeks

The chart below is the anchor. Everything else in this guide — what to expect, when to hold, how to convert units — builds off it. Bookmark this page: you'll be coming back.

Master Tirzepatide Titration Chart (FDA-Approved Schedule)

This is the standard titration schedule for both Mounjaro and Zepbound, pulled directly from prescribing information. Each dose level requires a minimum of 4 weeks before you can advance.

Phase	Week	Dose	Notes
Starter	1–4	2.5 mg	Tolerability period — not a weight loss dose
Maintenance 1	5–8	5 mg	First therapeutic dose; most people see meaningful appetite reduction
Maintenance 2	9–12	7.5 mg	Transitional — GI side effects often peak here
Maintenance 3	13–16	10 mg	Optimal dose for many long-term users
Maintenance 4	17–20	12.5 mg	Pre-max dose; diminishing returns for some
Maximum	21+	15 mg	Highest approved dose; reserved for those needing it

At the fastest pace, you reach 15 mg at week 21 (just under 5 months). That's only if you tolerate every dose increase cleanly. For most people, the realistic timeline is 6–10 months to find their sweet spot — and that's perfectly fine.

For a deeper breakdown of how the full tirzepatide dosage protocol works beyond just the chart, including dosing for type 2 diabetes vs. weight loss, see our full guide.

Printable Tirzepatide Dosage Chart

If you want the schedule on paper, on the fridge, or in a medication binder, here is the whole dosing chart in one table. Print the page (Ctrl+P on Windows, Cmd+P on Mac) and fill in the blanks week by week.

What this chart assumes: the mg column is the FDA-labeled schedule and applies to everyone. The volume column applies only to compounded tirzepatide from a vial labeled 10 mg/mL, drawn with a U-100 insulin syringe (100 units = 1 mL, so 1 unit = 0.01 mL). Brand-name pens are pre-measured, so if you use Mounjaro or Zepbound pens there is nothing to calculate. If your vial says anything other than 10 mg/mL, use the conversion tables further down instead.

Dose	Weeks at a 4-week pace	Draw from a 10 mg/mL vial	Date started	Weight
2.5 mg	1–4	0.25 mL = 25 units	________	________
5 mg	5–8	0.50 mL = 50 units	________	________
7.5 mg	9–12	0.75 mL = 75 units	________	________
10 mg	13–16	1.00 mL = 100 units	________	________
12.5 mg	17–20	1.25 mL = 125 units	________	________
15 mg	21+	1.50 mL = 150 units	________	________

A standard 1 mL U-100 insulin syringe tops out at 100 units, so the 12.5 mg and 15 mg rows need a larger syringe or a more concentrated vial. They are not an excuse to split the week into two half-doses on different days unless your prescriber told you to.

Four rules worth writing at the top of your printout:

Four weeks minimum on a dose before moving up. Longer is fine. Shorter is not.
One injection per week, same day each week. You can move the day as long as at least 72 hours separate two doses.
Missed a dose? Take it within 4 days (96 hours). Past that, skip it and take the next one on its normal day. Never double up.
Write your vial's concentration at the top before your first draw. The mg ladder is fixed; the volume is not.

Tirzepatide Weight Loss Dosage Chart vs. Diabetes Dosing

Same molecule, same ladder, but the two labels name different destinations. This is the part people miss when they copy a chart off a forum.

	Zepbound — weight loss	Zepbound — sleep apnea	Mounjaro — type 2 diabetes
Starting dose	2.5 mg weekly for 4 weeks	2.5 mg weekly for 4 weeks	2.5 mg weekly for 4 weeks
Is 2.5 mg a treatment dose?	No — initiation only, not approved as a maintenance dosage	No	No — "not intended for glycemic control"
Escalation	+2.5 mg after at least 4 weeks	+2.5 mg after at least 4 weeks	+2.5 mg after at least 4 weeks, if more glycemic control is needed
Named maintenance dosages	5 mg, 10 mg or 15 mg	10 mg or 15 mg	No fixed list — titrated to glycemic response
Maximum	15 mg	15 mg	15 mg in adults; 10 mg in pediatric patients

Two things follow. First, 7.5 mg and 12.5 mg are escalation rungs rather than the label's named maintenance dosages for weight loss — the master chart at the top of this page treats them as tiers because that is how they get used in practice, and holding there with your prescriber is a normal choice, but the label's maintenance list is 5, 10 and 15 mg. Second, if you are taking Zepbound for obstructive sleep apnea instead of weight, the label does not stop at 5 mg: maintenance starts at 10 mg.

What to Expect at Each Dose Tier

Knowing the dose number isn't enough. Here's what actually happens in your body — and in your life — as you move through the schedule.

2.5 mg (Weeks 1–4): The Warmup

This dose is designed to introduce your GI system to the medication, not to produce weight loss. Nausea is most common during this phase but is usually mild. Expect reduced appetite within the first week or two — that's the GIP/GLP-1 mechanism kicking in. Don't be discouraged if the scale doesn't move much. Your body is adjusting.

What patients commonly report:

Mild nausea, especially 4–8 hours after injection
Noticeably smaller appetite
Some constipation or loose stools
Occasional fatigue on injection day

5 mg (Weeks 5–8): First Real Results

This is where most people start losing weight meaningfully. The 5 mg dose is the first full maintenance dose. Appetite suppression gets noticeably stronger, and most people find they're naturally eating significantly less without feeling deprived. GI effects often improve here compared to the 2.5 mg transition.

Clinical data: In the SURMOUNT-1 trial, participants at 5 mg lost an average of ~15% of body weight over 72 weeks (compared to ~21% at 15 mg).

7.5 mg (Weeks 9–12): The Transition Bump

Expect a potential resurgence of nausea at this tier. The 7.5 mg step is often where people feel side effects the most sharply, especially if they rushed through the early doses. Slow down here if needed. Staying at 7.5 mg for 6–8 weeks instead of 4 is a legitimate, prescriber-supported choice.

10 mg (Weeks 13–16): The Sweet Spot for Many

The 10 mg dose has the best efficacy-to-tolerability ratio for most users. Many people find this is where they want to stay long-term. Weight loss continues at a strong pace and side effects tend to stabilize. If you're consistently losing 0.5–1% of body weight per week and tolerating it well, there's no clinical obligation to go higher.

12.5 mg (Weeks 17–20): Pre-Max

Marginal additional benefit over 10 mg for many patients, but some see meaningful improvement in blood sugar control or weight loss resumption after a plateau. GI tolerance varies significantly here — some people handle it easily, others find it rough.

15 mg (Week 21+): Maximum Dose

The highest FDA-approved dose. Clinical trials show the greatest average weight loss at this tier, but the incremental gain over 10 mg is smaller than going from 5 mg to 10 mg. Reserve this dose for patients who haven't reached target weight and are tolerating lower doses well.

Dose-Weight Loss Correlation Table

Based on SURMOUNT-1 and SURPASS clinical trial data (72 weeks of treatment):

Dose	Average Weight Loss (% of body weight)	Average Weight Loss (lbs, 250 lb baseline)	Time to Plateau
5 mg	~15%	~37 lbs	~52–60 weeks
10 mg	~19.5%	~49 lbs	~60–72 weeks
15 mg	~20.9%	~52 lbs	~72 weeks

Note: Individual results vary significantly. These are mean values from controlled clinical trials. Real-world results often differ based on diet, activity, and adherence.

Want to see how real people's results compare across the full protocol? Check out our tirzepatide before and after case breakdowns.

Tirzepatide Tolerability Chart: Side Effects by Dose

Efficacy climbs with the dose. Tolerability does not collapse the way people expect, and one of the most common side effects actually gets less common as the dose goes up. These are the pooled rates from the two placebo-controlled Zepbound weight-management trials, up to 72 weeks of treatment, as printed in the current FDA label.

Side effect	Placebo (n=958)	5 mg (n=630)	10 mg (n=948)	15 mg (n=941)
Nausea	8%	25%	29%	28%
Diarrhea	8%	19%	21%	23%
Vomiting	2%	8%	11%	13%
Constipation	5%	17%	14%	11%
Abdominal pain	5%	9%	9%	10%
Dyspepsia (indigestion)	4%	9%	9%	10%
Injection site reactions	2%	6%	8%	8%
Fatigue	3%	5%	6%	7%
Burping (eructation)	1%	4%	5%	5%
Hair loss	1%	5%	4%	5%
Acid reflux (GERD)	2%	4%	4%	5%

How to read it:

Nausea barely moves between 5 mg and 15 mg (25% to 28%). The tier you are on matters less than the week you are in — the label notes that most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time.
Vomiting and diarrhea are the two that genuinely track dose. Vomiting runs 8% at 5 mg and 13% at 15 mg.
Constipation runs backwards, from 17% at 5 mg down to 11% at 15 mg.

Tolerability measure	Placebo	5 mg	10 mg	15 mg
Any GI adverse reaction	30%	56%	56%	56%
Stopped treatment due to any adverse reaction	3.4%	4.8%	6.3%	6.7%
Stopped treatment due to GI reactions specifically	0.5%	1.9%	3.3%	4.3%

The headline number is that total GI side effects sat at 56% at every maintenance dose — 5 mg is not the "gentle" dose people assume it is; the mix of symptoms changes more than the overall rate. And about 93% of patients on 15 mg did not stop treatment over side effects. Of those who did quit, most did so in the first few months, during escalation.

Mounjaro Pen Sizes vs. Zepbound: What's the Same, What's Different

The active ingredient is identical: tirzepatide. The titration schedule is identical. What's different is the indication, the packaging, and some pen form factors.

Feature	Mounjaro	Zepbound
FDA Indication	Type 2 diabetes management	Chronic weight management; obstructive sleep apnea (with obesity)
Manufacturer	Eli Lilly	Eli Lilly
Starting dose	2.5 mg weekly	2.5 mg weekly
Max dose	15 mg weekly	15 mg weekly
Pen format	Single-dose autoinjector pen	Single-dose autoinjector pen; also available as vials
Available strengths	2.5, 5, 7.5, 10, 12.5, 15 mg/0.5 mL	2.5, 5, 7.5, 10, 12.5, 15 mg/0.5 mL
Pen color coding	Yes (each dose is a distinct color)	Yes (each dose is a distinct color)
Storage	Refrigerated; can be kept at room temp up to 21 days	Refrigerated; can be kept at room temp up to 21 days

Bottom line: If you have a Mounjaro prescription but want it for weight loss, or vice versa, the dosing is identical. Insurance coverage is the main practical difference — Zepbound is more likely to be covered under weight loss benefits; Mounjaro under diabetes benefits. If coverage falls through, see what Mounjaro costs without insurance.

Multi-Dose Vials and the KwikPen: The 2026 Additions

Both labels now list two presentations beyond the single-dose pen and single-dose vial: a multi-dose vial and a single-patient-use KwikPen. Each holds 2.4 mL, which is four weekly doses of 0.6 mL. The dose you get is unchanged; the container and the concentration are what differ.

Dose per injection	Total strength per vial/pen	Concentration	Volume per dose
2.5 mg	10 mg/2.4 mL	4.17 mg/mL	0.6 mL
5 mg	20 mg/2.4 mL	8.33 mg/mL	0.6 mL
7.5 mg	30 mg/2.4 mL	12.5 mg/mL	0.6 mL
10 mg	40 mg/2.4 mL	16.7 mg/mL	0.6 mL
12.5 mg	50 mg/2.4 mL	20.8 mg/mL	0.6 mL
15 mg	60 mg/2.4 mL	25 mg/mL	0.6 mL

Every strength is built to land on the same 0.6 mL draw, which is the whole point: you pull to the same mark every week regardless of tier. The label tells prescribers to have vial users take "a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose" — on a U-100 insulin syringe, that 0.6 mL reads as 60 units. Note also that the multi-dose presentations contain preservatives (benzyl alcohol and phenol) that the single-dose pen and vial do not, which matters if you have reacted to benzyl alcohol before.

Storage rules diverge here, and this is what catches people out:

Single-dose pen or single-dose vial: refrigerated, or up to a total of 21 days at room temperature (not above 30°C/86°F), then discard.
Unopened multi-dose vial or KwikPen: good until the labeled expiration date in the fridge, but only 30 days if kept at room temperature.
Opened multi-dose vial or KwikPen: discard after 4 weekly doses, 30 days after first use, or 30 total days at room temperature — whichever comes first, even if medicine is left in it.

Slow Titration Schedule: For GI-Sensitive Patients

Some providers recommend staying at each dose for 6–8 weeks instead of 4. This is particularly common for:

People with a history of severe GI reactions to medications
Patients who experienced significant nausea at the 2.5 mg or 5 mg tier
Those seeing good results at a lower dose without reason to rush higher

Weeks	Dose	Duration at Dose
1–8	2.5 mg	8 weeks
9–16	5 mg	8 weeks
17–24	7.5 mg	8 weeks
25–32	10 mg	8 weeks
33–40	12.5 mg	8 weeks
41+	15 mg	Ongoing

Reaching 15 mg on this schedule takes about 40 weeks (~10 months). The tradeoff — fewer side effects, more gradual progression — is worth it for many patients.

Compounded Tirzepatide Dosage Chart: mL and Units Conversion

Compounded tirzepatide comes in multi-dose vials at varying concentrations. The dose in milligrams is the same as brand-name; the difference is you draw your dose using a syringe, and you need to convert mg → units based on your vial's concentration.

How to calculate your draw volume:
Units to draw = (Dose in mg ÷ Concentration in mg/mL) × 100

At 10 mg/mL Concentration (Most Common)

Dose	Volume (mL)	Units to Draw (U-100 syringe)
2.5 mg	0.25 mL	25 units
5 mg	0.50 mL	50 units
7.5 mg	0.75 mL	75 units
10 mg	1.00 mL	100 units
12.5 mg	1.25 mL	125 units*
15 mg	1.50 mL	150 units*

*May require a 1.5 mL syringe or two injections.

At 5 mg/mL Concentration

Dose	Volume (mL)	Units to Draw (U-100 syringe)
2.5 mg	0.50 mL	50 units
5 mg	1.00 mL	100 units
7.5 mg	1.50 mL	150 units*
10 mg	2.00 mL	200 units*

*Requires multiple injections; 5 mg/mL is not recommended for doses above 5 mg.

At 20 mg/mL Concentration

Dose	Volume (mL)	Units to Draw (U-100 syringe)
2.5 mg	0.125 mL	~13 units
5 mg	0.25 mL	25 units
7.5 mg	0.375 mL	~38 units
10 mg	0.50 mL	50 units
12.5 mg	0.625 mL	~63 units
15 mg	0.75 mL	75 units

Always confirm the concentration on your vial label before drawing. Compounding pharmacies use different concentrations, and a dosing error at a higher concentration can mean a significant accidental overdose.

When to Hold vs. When to Advance Your Dose

This is the decision most people get wrong — either rushing up too fast or staying at a dose that's no longer working. Here's a practical framework:

✅ Advance to the Next Dose When:

You've been at the current dose for at least 4 weeks (or 6–8 weeks on a slow protocol)
Side effects from the current dose have resolved or are minimal
Weight loss has stalled for 3+ consecutive weeks at the current dose
Your prescriber agrees based on your check-in

⏸ Hold at Your Current Dose When:

You're still actively losing weight (there's no reason to rush higher)
Side effects are present but improving week over week
You've just recovered from an illness, surgery, or significant stress
You're entering a travel period and don't want to adjust variables

⬇ Drop Back a Dose When:

Nausea, vomiting, or diarrhea is severe and not improving after 2 weeks
You've lost more than 1.5% of body weight per week for 3+ consecutive weeks (too fast)
Your prescriber recommends it based on labs or clinical assessment
You feel physically depleted (muscle loss signs, fatigue, inability to eat)

One key principle: The goal is the dose that works, not the highest dose possible. Plenty of people have excellent, sustainable results at 5 mg or 7.5 mg. Chasing 15 mg when 10 mg is working is counterproductive.

For a complete breakdown of what happens at each dose, including how to manage the side effect profile by tier, see our tirzepatide side effects guide.

Missed Dose Protocol

Tirzepatide's long half-life (~5 days) gives you some flexibility:

Missed by ≤4 days: Take it as soon as you remember, then resume your normal weekly schedule
Missed by >4 days: Skip the missed dose entirely — take your next dose on your regularly scheduled day
Never double-dose to compensate for a missed injection

If you miss two consecutive doses, GI side effects may return when you restart, similar to starting fresh. Talk to your prescriber if you anticipate a prolonged interruption.

CTA: Need a Reliable Source for Tirzepatide?

If you're looking for compounded tirzepatide from a verified, quality-tested source, Synthro Lab is one of the most trusted options available. Every batch is triple-tested to at least 99% HPLC purity, a certificate of analysis comes with every order, and the QR code on the label resolves to that batch's certificate. They lyophilize domestically and dispatch same day, ship to the US, EU and Australia with free shipping over $250, and stand behind it with a 30-day money-back guarantee.

Frequently Asked Questions

Q: Can I stay at 2.5 mg long-term if it's working?
A: The 2.5 mg dose is considered a tolerability starter dose, not a maintenance dose. Clinical trials used 5 mg as the minimum maintenance dose for weight loss. Most prescribers will encourage moving to 5 mg after 4 weeks. If you're seeing results, staying at 5 mg is a much more supported choice than staying at 2.5 mg.

Q: What if I feel terrible at 5 mg — do I have to push through?
A: No. If side effects are severe, you can drop back to 2.5 mg and wait until symptoms resolve before trying 5 mg again. You can also slow the ramp by extending time at each tier to 6–8 weeks. The goal is tolerability, not speed.

Q: Is the compounded tirzepatide titration schedule the same as brand-name?
A: The mg doses are identical. The difference is how you measure and administer them — compounded comes in vials requiring syringe draws, so you need to account for concentration. Always verify your calculation before injecting.

Q: How is Mounjaro different from Zepbound if they're the same drug?
A: The molecule (tirzepatide) and dosing schedule are identical. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. The primary difference in practice is insurance coverage — which indication is covered depends on your plan.

Q: What's the maximum dose of tirzepatide?
A: 15 mg per week is the maximum FDA-approved dose for both Mounjaro and Zepbound. Some compounding protocols go higher, but there is no clinical trial data supporting doses above 15 mg and the risk-benefit ratio is unknown.

Q: Why does the titration schedule take so long?
A: GLP-1 and GIP receptor agonists like tirzepatide affect the GI system significantly. Moving too fast through dose increases overwhelms the digestive system and causes the nausea, vomiting, and diarrhea that lead most people to quit. The 4-week minimum at each tier isn't arbitrary — it's the minimum time needed for GI adaptation to stabilize.

Q: Can I split my weekly dose into two injections to reduce side effects?
A: This is sometimes done with compounded tirzepatide (since you control the syringe volume), but it's off-label and not supported by Mounjaro/Zepbound autoinjector pens. Some providers recommend split dosing for patients with persistent nausea. Discuss with your prescriber before attempting this.

Q: Which tirzepatide dose has the worst side effects?
A: There isn't a single bad tier. In the pooled Zepbound trials, nausea was 25% at 5 mg, 29% at 10 mg and 28% at 15 mg, while constipation ran the other direction — 17%, 14%, then 11%. Only vomiting and diarrhea clearly track the dose. Total GI side effects were 56% at all three maintenance doses. What changes most is timing: escalation weeks are rougher than steady weeks, at every tier.

Q: Do the multi-dose vials and KwikPens change the titration schedule?
A: No. The mg ladder and the 4-week minimum are identical. A multi-dose vial or KwikPen holds 2.4 mL — four weekly doses of 0.6 mL at whichever strength you were prescribed — and gets thrown away after those 4 doses or 30 days from first use, whichever comes first.

Quick Reference Summary

Dose	Brand Pen Available	Min. Duration	Expected Weekly Weight Loss	Common Side Effects
2.5 mg	Mounjaro / Zepbound	4 weeks	Minimal (tolerability phase)	Nausea, appetite changes
5 mg	Mounjaro / Zepbound	4 weeks	0.5–1% of body weight	Nausea (reducing), constipation
7.5 mg	Mounjaro / Zepbound	4 weeks	0.5–1% of body weight	GI peak — nausea possible
10 mg	Mounjaro / Zepbound	4 weeks	0.5–1% of body weight	Side effects typically stabilize
12.5 mg	Mounjaro / Zepbound	4 weeks	0.4–0.8% of body weight	Variable
15 mg	Mounjaro / Zepbound	Ongoing	0.3–0.7% of body weight	GI effects may recur at max

This content is for informational purposes only and does not constitute medical advice. Tirzepatide is a prescription medication. Dosing decisions should be made in consultation with a licensed healthcare provider. Individual results vary. The titration schedule above reflects FDA-approved prescribing information for Mounjaro and Zepbound as of the publication date.